Connor, Clark & Lunn Investment Management (CC&L)’s Cullinan Oncology CGEM Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio CGEM Stock Details CGEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.33M	Buy	292,500 +3,385	+1%	+$50.3K	0.01%	711
2026 Q1	$4.11M	Buy	289,115 +45,093	+18%	+$580K	0.01%	740
2025 Q4	$2.53M	Buy	244,022 +104,998	+76%	+$947K	0.01%	857
2025 Q3	$824K	Buy	139,024 +68,980	+98%	+$505K	﹤0.01%	1123
2025 Q2	$527K	Sell	70,044 -7,577	-10%	-$60.9K	﹤0.01%	1238
2025 Q1	$588K	Buy	77,621 +57,348	+283%	+$550K	﹤0.01%	1099
2024 Q4	$247K	Buy	+20,273	New	+$291K	﹤0.01%	1292
2024 Q2	–	Sell	-36,401	Closed	-$620K	–	1414
2024 Q1	$620K	Buy	+36,401	New	+$562K	﹤0.01%	1046

Other funds holding CGEM

MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s CGEM Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its Cullinan Oncology (CGEM) stake by 1.2% in Q2 2026, buying an estimated $50.3K and bringing the position to 292,500 shares worth $5.33M. The position accounts for 0.01% of the portfolio, ranked #711.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in CGEM in Q1 2024 and has held it in 8 quarters since. 183 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 292,500 shares of Cullinan Oncology worth $5.33M as of Q2 2026.
Connor, Clark & Lunn Investment Management (CC&L) bought 3,385 Cullinan Oncology shares in Q2 2026, an estimated $50.3K.
Cullinan Oncology made up 0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #711 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Cullinan Oncology in Q1 2024 and has held it in 8 quarters since.
183 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.